The first product, developed from a new technological platform from Lesaffre that targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections.
Gnosis by Lesaffre (Marcq-En-Baroeul, France) introduceda phages-based ingredient line to help target specific pro-inflammatory or pathogenic bacteria in the gut and potentially enhance the gastrointestinal benefits of probiotics.
“Consumers recognize probiotics and how they support our digestive health and overall health,” said Philippe Caillat, Gnosis by Lesaffre’sglobal marketing director, in a press release. “That’s what pushed us to continue exploring solutions for targeted digestive disorders, such as abdominal pain, diarrhea, and gut flora restoration. Good gut health truly is the essence of a good life. We’re here to bring that to life with our new phages-based portfolio.”
The first product, developed from a new technological platform fromLesaffrethat targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections such as E.coli, Salmonella, and Listeria.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.